Bone health in breast cancer hormone-blockade patients
Part of Cancer, Skin clinical trials.
This study tracks bone health in breast cancer patients receiving hormone-blocking therapy (aromatase inhibitors, GnRH analogs, or tamoxifen). It aims to understand how these treatments affect bone mineral density.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have breast cancer and are receiving hormone-blocking therapy (such as aromatase inhibitors, GnRH analogs, or tamoxifen) as part of your adjuvant (post-surgery) treatment.
- You have had a bone density scan (densitometry) and blood tests related to bone metabolism.
- You have signed a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study looks at bone complications in post-menopausal women with breast cancer after stopping denosumab and an aromatase inhibitor. It may help doctors better understand who is at risk for bone weakening and fractures after these medicines are stopped.
This study tests a new drug called romosozumab, which may help strengthen bones and reduce fractures in people with breast cancer that has spread to the bones and who also have osteoporosis. If you are on hormone therapy and have weak bones, this could help protect your bones.
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
This study looks back at medical records of young women who had no menstrual period for at least 6 months. The goal is to understand how their bone density changed and what factors might have affected it.
This trial tests if a probiotic supplement can help prevent bone loss in women with HR-positive breast cancer who are starting an aromatase inhibitor. You would take the probiotic daily and provide blood and stool samples to see how it affects your bone health.
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.